Page last updated: 2024-08-21

pyrazines and carbostyril

pyrazines has been researched along with carbostyril in 15 studies

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (13.33)18.2507
2000's7 (46.67)29.6817
2010's5 (33.33)24.3611
2020's1 (6.67)2.80

Authors

AuthorsStudies
Hayashida, W; Kawai, C; Kumada, T1
Feldman, AM; Strobeck, JE1
Young, JB1
Bertolet, BD1
Alsina, M; Beaupre, DM; Buzzeo, R; Dalton, WS; Enkemann, S; Lichtenheld, MG; Nimmanapalli, R1
Beaupre, DM; Boulware, D; Buzzeo, RW; Colaco, NM; Dalton, WS; Parquet, NA; Perez, LE; Wright, G; Yanamandra, N1
Armand, JP; Burnett, AK; Drach, J; Harousseau, JL; Löwenberg, B; San Miguel, J1
Bonnefous, C; Chen, X; Hassig, CA; Nguyen, PM; Noble, SA; Payne, JE; Rao, TS; Rix, P; Roppe, J; Rozenkrants, N; Sablad, M; Severance, D; Shiau, AK; Smith, ND; Symons, KT; Walsh, JP; Wang, L; Yazdani, N; Zhang, Y; Zhuang, H1
Boise, LH; Chen, J; David, E; Flowers, CR; Kaufman, JL; Lonial, S; Marcus, AI; Schafer-Hales, K; Sun, SY; Torre, C1
Blaskovich, MA; Burton, M; Cubitt, C; Duong, VH; Lancet, JE; Sebti, S; Stuart, RK; Sullivan, DM; Winton, EF; Wright, JJ; Zhang, S1
Piao, HR; Wu, Y1
Batra, SK; Dhanasingh, I; Kanteti, R; Kaushik, G; Kindler, HL; Kulkarni, P; Mambetsariev, B; Mirzapoiazova, T; Nasser, MW; Ponnusamy, MP; Riehm, JJ; Salgia, R; Seshacharyulu, P; Wang, J1
De Koning, L; De Wolf, J; Jaurand, MC; Jean, D; Le Pimpec-Barthes, F; Meiller, C; Montagne, F; Quetel, L; Tranchant, R; Zucman-Rossi, J1
Xia, X1

Reviews

5 review(s) available for pyrazines and carbostyril

ArticleYear
[New oral drugs for the treatment of congestive heart failure].
    Nihon rinsho. Japanese journal of clinical medicine, 1992, Volume: 50, Issue:2

    Topics: Administration, Oral; Cardiotonic Agents; Deoxyepinephrine; Ethanolamines; Heart Failure; Humans; Phosphodiesterase Inhibitors; Piperidines; Propanolamines; Pyrazines; Quinolines; Quinolones; Vasodilator Agents; Xamoterol

1992
Quinolinone derivatives in the management of congestive heart failure.
    Coronary artery disease, 1994, Volume: 5, Issue:2

    Topics: Animals; Cardiotonic Agents; Heart Failure; Humans; Pyrazines; Quinolines; Quinolones

1994
Precautions for use and adverse effects of vesnarinone: potential mechanisms and future therapies.
    Drug safety, 2004, Volume: 27 Suppl 1

    Topics: Animals; Clinical Trials as Topic; Death, Sudden; Heart Failure; Humans; Monitoring, Physiologic; Multicenter Studies as Topic; Neutropenia; Pyrazines; Quinolines; Quinolones

2004
The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
    The oncologist, 2007, Volume: 12, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Hematologic Neoplasms; Humans; Pyrazines; Quinolones

2007
The progress towards the development of DHQO derivatives and related analogues with inotropic effects.
    Mini reviews in medicinal chemistry, 2013, Volume: 13, Issue:12

    Topics: Animals; Cardiotonic Agents; Pyrazines; Quinolines; Quinolones; Rabbits; Stroke Volume; Structure-Activity Relationship

2013

Trials

1 trial(s) available for pyrazines and carbostyril

ArticleYear
A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Mar-01, Volume: 17, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chymotrypsin; Farnesyltranstransferase; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; NF-kappa B; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Inhibitors; Pyrazines; Quinolones

2011

Other Studies

9 other study(ies) available for pyrazines and carbostyril

ArticleYear
The best of times, the worst of times: the wealth and poverty of heart failure pharmacotherapies: is there a role for vesnarinone?
    Drug safety, 2004, Volume: 27 Suppl 1

    Topics: Clinical Trials as Topic; Drug Therapy; Forecasting; Heart Failure; Humans; Pyrazines; Quinolines; Quinolones; Socioeconomic Factors; Time Factors

2004
Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-15, Volume: 11, Issue:16

    Topics: Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Melphalan; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Phenotype; Protease Inhibitors; Protein Prenylation; Pyrazines; Quinolones; ras Proteins; Staurosporine; Tunicamycin

2005
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jan-15, Volume: 12, Issue:2

    Topics: Antineoplastic Agents; Bone Marrow; Boronic Acids; Bortezomib; Cell Adhesion; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fibronectins; Humans; Leukemia, Myeloid, Acute; Multiple Myeloma; Pyrazines; Quinolones; Stromal Cells; Tumor Cells, Cultured

2006
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
    Clinical lymphoma & myeloma, 2007, Volume: 7, Issue:4

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Drug Therapy, Combination; Hematologic Diseases; Hematology; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Multiple Myeloma; Prednisone; Pyrazines; Quinolones; Recurrence; Stem Cell Transplantation; Thalidomide; Transplantation Conditioning; Transplantation, Autologous

2007
Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models.
    Journal of medicinal chemistry, 2009, May-14, Volume: 52, Issue:9

    Topics: Administration, Oral; Animals; Cell Line; Constriction, Pathologic; Disease Models, Animal; Drug Discovery; Enzyme Inhibitors; Fluoroquinolones; Formaldehyde; Humans; Inhibitory Concentration 50; Lipopolysaccharides; Mice; Nitric Oxide Synthase Type II; Pain; Protein Multimerization; Protein Structure, Quaternary; Pyrazines; Quinolones; Structure-Activity Relationship; Substrate Specificity

2009
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes.
    Blood, 2010, Dec-09, Volume: 116, Issue:24

    Topics: Apoptosis; Autophagy; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Humans; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Quinolones; Ubiquitination

2010
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
    Cancer biology & therapy, 2018, 04-03, Volume: 19, Issue:4

    Topics: Animals; Benzamides; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Focal Adhesion Kinase 1; Focal Adhesion Kinase 2; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Transgenic; Neoplasms, Experimental; Pancreatic Neoplasms; Phosphorylation; Pleural Neoplasms; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinolones; Sulfonamides; Sulfones

2018
Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.
    Lung cancer (Amsterdam, Netherlands), 2018, Volume: 126

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesothelioma; Phenols; Pleural Neoplasms; Pyrazines; Quinolones; RNA Interference; Signal Transduction; Sulfonamides; Tumor Cells, Cultured; Verteporfin

2018
Drug efficacy and toxicity prediction: an innovative application of transcriptomic data.
    Cell biology and toxicology, 2020, Volume: 36, Issue:6

    Topics: Aminophenols; Aminopyridines; Animals; Antineoplastic Agents; Benzodioxoles; Cell Death; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Combinations; Drug Development; Epithelial Cells; Gene Expression Profiling; Gene Regulatory Networks; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyrazoles; Quinolones; Toxicity Tests; Transcriptome

2020